Wells Fargo & Company Increases Omnicell (NASDAQ:OMCL) Price Target to $41.00

Omnicell (NASDAQ:OMCL) had its price objective upped by equities research analysts at Wells Fargo & Company from $30.00 to $41.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential downside of 3.26% from the stock’s previous close.

OMCL has been the subject of a number of other reports. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, October 10th. Benchmark reissued a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $26.00 to $39.00 in a report on Friday, August 2nd. Bank of America raised their price objective on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Omnicell Stock Performance

NASDAQ:OMCL opened at $42.38 on Monday. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The company has a market cap of $1.95 billion, a P/E ratio of -92.13, a P/E/G ratio of 47.35 and a beta of 0.83. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $45.84. The firm’s 50 day moving average is $43.12 and its two-hundred day moving average is $34.04.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business’s revenue for the quarter was down 7.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.29 EPS. Analysts expect that Omnicell will post 0.64 EPS for the current year.

Institutional Trading of Omnicell

Several hedge funds have recently bought and sold shares of OMCL. Nisa Investment Advisors LLC lifted its position in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after purchasing an additional 1,000 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares in the last quarter. EntryPoint Capital LLC raised its position in shares of Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares in the last quarter. CWM LLC raised its position in shares of Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after buying an additional 1,236 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.